181 related articles for article (PubMed ID: 19762089)
1. Sodium valproate: an old drug with new roles.
Nalivaeva NN; Belyaev ND; Turner AJ
Trends Pharmacol Sci; 2009 Oct; 30(10):509-14. PubMed ID: 19762089
[TBL] [Abstract][Full Text] [Related]
2. Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.
Harrison IF; Crum WR; Vernon AC; Dexter DT
Br J Pharmacol; 2015 Aug; 172(16):4200-15. PubMed ID: 26040297
[TBL] [Abstract][Full Text] [Related]
3. Repurposing of sodium valproate in colon cancer associated with diabetes mellitus: Role of HDAC inhibition.
Patel MM; Patel BM
Eur J Pharm Sci; 2018 Aug; 121():188-199. PubMed ID: 29852291
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate.
Demyanenko SV; Dzreyan VA; Uzdensky AB
Brain Res Bull; 2020 Sep; 162():151-165. PubMed ID: 32592806
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke.
Faggi L; Pignataro G; Parrella E; Porrini V; Vinciguerra A; Cepparulo P; Cuomo O; Lanzillotta A; Mota M; Benarese M; Tonin P; Annunziato L; Spano P; Pizzi M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316653
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
Ziemka-Nalecz M; Jaworska J; Sypecka J; Zalewska T
J Neuropathol Exp Neurol; 2018 Oct; 77(10):855-870. PubMed ID: 30165682
[TBL] [Abstract][Full Text] [Related]
7. Sodium valproate enhances doxorubicin-induced cognitive dysfunction in Wistar rats.
Verma T; Mallik SB; Ramalingayya GV; Nayak PG; Kishore A; Pai KSR; Nandakumar K
Biomed Pharmacother; 2017 Dec; 96():736-741. PubMed ID: 29049976
[TBL] [Abstract][Full Text] [Related]
8. Valproate and neuroprotection.
Vajda FJ
J Clin Neurosci; 2002 Sep; 9(5):508-14. PubMed ID: 12383405
[No Abstract] [Full Text] [Related]
9. Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to neuroprotection during cardiac surgery.
Williams JA; Barreiro CJ; Nwakanma LU; Lange MS; Kratz LE; Blue ME; Berrong J; Patel ND; Gott VL; Troncoso JC; Johnston MV; Baumgartner WA
Ann Thorac Surg; 2006 Jun; 81(6):2235-41; discussion 2241-2. PubMed ID: 16731160
[TBL] [Abstract][Full Text] [Related]
10. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.
Leng Y; Chuang DM
J Neurosci; 2006 Jul; 26(28):7502-12. PubMed ID: 16837598
[TBL] [Abstract][Full Text] [Related]
11. Tescalcin is a potential target of class I histone deacetylase inhibitors in neurons.
Takamatsu G; Katagiri C; Tomoyuki T; Shimizu-Okabe C; Nakamura W; Nakamura-Higa M; Hayakawa T; Wakabayashi S; Kondo T; Takayama C; Matsushita M
Biochem Biophys Res Commun; 2017 Jan; 482(4):1327-1333. PubMed ID: 27939885
[TBL] [Abstract][Full Text] [Related]
12. New perspectives of valproic acid in clinical practice.
Činčárová L; Zdráhal Z; Fajkus J
Expert Opin Investig Drugs; 2013 Dec; 22(12):1535-47. PubMed ID: 24160174
[TBL] [Abstract][Full Text] [Related]
13. Targeting histone acetylation for neuroprotection.
Contestabile A
Curr Pharm Des; 2013; 19(28):5017-8. PubMed ID: 23448467
[No Abstract] [Full Text] [Related]
14. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.
Löscher W
CNS Drugs; 2002; 16(10):669-94. PubMed ID: 12269861
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.
Perucca E
CNS Drugs; 2002; 16(10):695-714. PubMed ID: 12269862
[TBL] [Abstract][Full Text] [Related]
16. [Valproic acid as a histone deacetylase inhibitor. New application for a well-known drug].
Wagner JM; Bug G; Jung M
Pharm Unserer Zeit; 2010 May; 39(3):197-203. PubMed ID: 20425769
[No Abstract] [Full Text] [Related]
17. Sodium Valproate, a Histone Deacetylase Inhibitor, Provokes Reactive Oxygen Species-Mediated Cytotoxicity in Human Hepatocellular Carcinoma Cells.
Rithanya P; Ezhilarasan D
J Gastrointest Cancer; 2021 Mar; 52(1):138-144. PubMed ID: 32006341
[TBL] [Abstract][Full Text] [Related]
18. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection.
Monti B; Polazzi E; Contestabile A
Curr Mol Pharmacol; 2009 Jan; 2(1):95-109. PubMed ID: 20021450
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors and neurodegeneration: at the edge between protection and damage.
Dietz KC; Casaccia P
Pharmacol Res; 2010 Jul; 62(1):11-7. PubMed ID: 20123018
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Kim HJ; Rowe M; Ren M; Hong JS; Chen PS; Chuang DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):892-901. PubMed ID: 17371805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
